A blood-based machine learning assay that combines cell-free DNA (cfDNA) fragment patterns and levels of the proteins CA125 and HE4 could differentiate patients with ovarian cancer from healthy controls or patients with benign ovarian masses, according to a retrospective study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10. Federal ..read more

A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine. Combining the highly specific huAR9.6 antibody with PET and therapeutic radionuclides, this theranostic platform may provide more personalised treatment to improve health outcomes for ovarian cancer patients ..read more

Some anti-cancer treatments not only target tumour cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with Basel-based FoRx Therapeutics, has identified the mechanism of action of PARP inhibitors, used in particular for breast and ..read more

Today, three ovarian cancer research institutions have received significant funding from the Ovarian Cancer Research Foundation (OCRF) through their annual National Research Grants Scheme. Totalling over $2 million, the grants will enable Australian researchers to investigate solutions across ovarian cancer diagnostics and treatment, with the aim to improve patient outcomes today and long-term survival rates ..read more

In ovarian cancer, the abnormal expression of various metabolic enzymes in the metabolism of polyunsaturated fatty acids (PUFA) is involved in the development of tumours and immune regulation. Most of the patients are admitted with advanced disease, due to the hidden symptoms and difficulty in detecting at early stage. The chemoresistance to standard platinum-based chemotherapy ..read more

Researchers at the Johns Hopkins Kimmel Cancer Center and the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine, USA, have developed an algorithm to identify high-risk precancerous lesions on the fallopian tubes. Known as serous tubal intraepithelial carcinomas (STICs), these lesions are thought to be the main precursors of ovarian ..read more

A new research paper was published in Oncotarget‘s Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.” In this new exploratory and descriptive study, researchers from Vito Fazzi Hospital, University of Salento, Strategic Regional ..read more

In a major scientific breakthrough, newly published research from an international consortium led by the University of Minnesota’s Masonic Cancer Center, USA, has the potential to transform the landscape of ovarian cancer treatment. Published today in JAMA Network Open, the findings indicate that ovarian cancer patients with high levels of stroma within their tumours are twice as ..read more

CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients with the deadliest form ovarian cancer. Elenagen belongs to a novel class of biological agents, supercoiled circular DNA (plasmids). The study, published in Frontiers in Oncology, shows that ..read more

Women diagnosed with ovarian cancer may initially respond well to chemotherapy, but the majority of them will develop resistance to treatment and die from the disease. Now Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how to sneakily use that to destroy it. In ..read more